We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants

MedXY Editorial Team•Dec 29, 2025•Diabetes & Endocrinology
diabetesimmunotherapyoncology

Highlights

Analysis of 13,966 patients across 158 National Cancer Institute (NCI) trials highlights that immune checkpoint inhibitor-induced diabetes (ICI-D) has an overall cumulative incidence of 0.52%.

The risk of ICI-D is significantly higher with combination immunotherapy (OR 2.68) compared to PD-1/PD-L1 monotherapy, whereas concurrent chemotherapy appears to reduce the risk (OR 0.38).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Mortality and Morbidity After Below-Knee Amputation in Diabetes: Insights from a 25-Year English Cohort StudyThis large-scale England study reveals persistently high mortality after below-knee amputation in diabetes, with one-year mortality exceeding 23%, emphasizing the need for targeted interventions focused on older, female, and comorbid patienSep 17, 2026Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical TrialFive-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.Sep 15, 2026Global Trends in the Burden of Ischemic Stroke Attributable to Diabetes Versus Atrial FibrillationThis study analyzes global trends comparing ischemic stroke burdens linked to diabetes and atrial fibrillation, revealing a rising impact of diabetes-related stroke and highlighting the need for targeted interventions.Sep 12, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.
Sep 6, 2026
Charcot Neuro-Osteoarthropathy in Diabetes: High Risk of Hospitalization, Amputation, and Mortality Revealed by Regional Cohort StudyCharcot neuro-osteoarthropathy (CNO) in people with diabetes is linked to frequent emergency hospitalizations, substantial risk of limb amputation, and reduced survival, highlighting urgent need for intensified multidisciplinary care.Sep 5, 2026
Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple MyelomaMezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.Sep 3, 2026